The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Breast Neoplasms

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Breast Neoplasms


Psychiatry related information on Breast Neoplasms


High impact information on Breast Neoplasms


Chemical compound and disease context of Breast Neoplasms


Biological context of Breast Neoplasms


Anatomical context of Breast Neoplasms


Gene context of Breast Neoplasms


Analytical, diagnostic and therapeutic context of Breast Neoplasms


  1. The benefit and cost of prostate cancer early detection. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project. Littrup, P.J., Goodman, A.C., Mettlin, C.J. CA: a cancer journal for clinicians. (1993) [Pubmed]
  2. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. Diel, I.J., Solomayer, E.F., Costa, S.D., Gollan, C., Goerner, R., Wallwiener, D., Kaufmann, M., Bastert, G. N. Engl. J. Med. (1998) [Pubmed]
  3. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. Couch, F.J., DeShano, M.L., Blackwood, M.A., Calzone, K., Stopfer, J., Campeau, L., Ganguly, A., Rebbeck, T., Weber, B.L. N. Engl. J. Med. (1997) [Pubmed]
  4. Mutational and functional analyses reveal that ST7 is a highly conserved tumor-suppressor gene on human chromosome 7q31. Zenklusen, J.C., Conti, C.J., Green, E.D. Nat. Genet. (2001) [Pubmed]
  5. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. Struewing, J.P., Hartge, P., Wacholder, S., Baker, S.M., Berlin, M., McAdams, M., Timmerman, M.M., Brody, L.C., Tucker, M.A. N. Engl. J. Med. (1997) [Pubmed]
  6. The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Welm, A.L., Sneddon, J.B., Taylor, C., Nuyten, D.S., van de Vijver, M.J., Hasegawa, B.H., Bishop, J.M. Proc. Natl. Acad. Sci. U.S.A. (2007) [Pubmed]
  7. A prospective study of folate intake and the risk of breast cancer. Zhang, S., Hunter, D.J., Hankinson, S.E., Giovannucci, E.L., Rosner, B.A., Colditz, G.A., Speizer, F.E., Willett, W.C. JAMA (1999) [Pubmed]
  8. Meta-analysis: dietary fat intake, serum estrogen levels, and the risk of breast cancer. Wu, A.H., Pike, M.C., Stram, D.O. J. Natl. Cancer Inst. (1999) [Pubmed]
  9. Breast cancer risk reduction: strategies for women at increased risk. Chlebowski, R.T. Annu. Rev. Med. (2002) [Pubmed]
  10. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. Bober, S.L., Hoke, L.A., Duda, R.B., Regan, M.M., Tung, N.M. J. Clin. Oncol. (2004) [Pubmed]
  11. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. Loprinzi, C.L., Abu-Ghazaleh, S., Sloan, J.A., vanHaelst-Pisani, C., Hammer, A.M., Rowland, K.M., Law, M., Windschitl, H.E., Kaur, J.S., Ellison, N. J. Clin. Oncol. (1997) [Pubmed]
  12. Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer. Kudachadkar, R., O'Regan, R.M. CA: a cancer journal for clinicians. (2005) [Pubmed]
  13. Hormone replacement therapy in the menopause: a pro opinion. Smith, H.O., Kammerer-Doak, D.N., Barbo, D.M., Sarto, G.E. CA: a cancer journal for clinicians. (1996) [Pubmed]
  14. Primary chemotherapy in surgically resectable breast cancer. Bonadonna, G., Valagussa, P., Zucali, R., Salvadori, B. CA: a cancer journal for clinicians. (1995) [Pubmed]
  15. Role of progesterone receptors in breast cancer. McGuire, W.L., Clark, G.M. CA: a cancer journal for clinicians. (1986) [Pubmed]
  16. Hormone-replacement therapy and the risk of breast cancer. Hulka, B.S. CA: a cancer journal for clinicians. (1990) [Pubmed]
  17. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. Bonadonna, G., Valagussa, P., Moliterni, A., Zambetti, M., Brambilla, C. N. Engl. J. Med. (1995) [Pubmed]
  18. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. Muss, H.B., Case, L.D., Richards, F., White, D.R., Cooper, M.R., Cruz, J.M., Powell, B.L., Spurr, C.L., Capizzi, R.L. N. Engl. J. Med. (1991) [Pubmed]
  19. Progression to steroid insensitivity can occur irrespective of the presence of functional steroid receptors. Darbre, P.D., King, R.J. Cell (1987) [Pubmed]
  20. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. Colditz, G.A., Hankinson, S.E., Hunter, D.J., Willett, W.C., Manson, J.E., Stampfer, M.J., Hennekens, C., Rosner, B., Speizer, F.E. N. Engl. J. Med. (1995) [Pubmed]
  21. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs. Spänkuch, B., Kurunci-Csacsko, E., Kaufmann, M., Strebhardt, K. Oncogene (2007) [Pubmed]
  22. Plasma protein carbonyl levels and breast cancer risk. Rossner, P., Terry, M.B., Gammon, M.D., Agrawal, M., Zhang, F.F., Ferris, J.S., Teitelbaum, S.L., Eng, S.M., Gaudet, M.M., Neugut, A.I., Santella, R.M. J. Cell. Mol. Med. (2007) [Pubmed]
  23. Opportunities and strategies for breast cancer prevention through risk reduction. Mahoney, M.C., Bevers, T., Linos, E., Willett, W.C. CA. Cancer. J. Clin (2008) [Pubmed]
  24. Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models. Diamond, J.R., Eckhardt, S.G., Tan, A.C., Newton, T.P., Selby, H.M., Brunkow, K.L., Kachaeva, M.I., Varella-Garcia, M., Pitts, T.M., Bray, M.R., Fletcher, G.C., Tentler, J.J. Clin. Cancer Res. (2013) [Pubmed]
  25. Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease. Wardell, S.E., Nelson, E.R., Chao, C.A., McDonnell, D.P. Clin. Cancer Res. (2013) [Pubmed]
  26. Inhibition of RET increases the efficacy of antiestrogen and is a novel treatment strategy for luminal breast cancer. Spanheimer, P.M., Park, J.M., Askeland, R.W., Kulak, M.V., Woodfield, G.W., De Andrade, J.P., Cyr, A.R., Sugg, S.L., Thomas, A., Weigel, R.J. Clin. Cancer Res. (2014) [Pubmed]
  27. 89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients. Gaykema, S.B., Schröder, C.P., Vitfell-Rasmussen, J., Chua, S., Oude Munnink, T.H., Brouwers, A.H., Bongaerts, A.H., Akimov, M., Fernandez-Ibarra, C., Lub-de Hooge, M.N., de Vries, E.G., Swanton, C., Banerji, U. Clin. Cancer Res. (2014) [Pubmed]
  28. Growth retardation and tumour inhibition by BRCA1. Holt, J.T., Thompson, M.E., Szabo, C., Robinson-Benion, C., Arteaga, C.L., King, M.C., Jensen, R.A. Nat. Genet. (1996) [Pubmed]
  29. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Thorlacius, S., Olafsdottir, G., Tryggvadottir, L., Neuhausen, S., Jonasson, J.G., Tavtigian, S.V., Tulinius, H., Ogmundsdottir, H.M., Eyfjörd, J.E. Nat. Genet. (1996) [Pubmed]
  30. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Couch, F.J., Farid, L.M., DeShano, M.L., Tavtigian, S.V., Calzone, K., Campeau, L., Peng, Y., Bogden, B., Chen, Q., Neuhausen, S., Shattuck-Eidens, D., Godwin, A.K., Daly, M., Radford, D.M., Sedlacek, S., Rommens, J., Simard, J., Garber, J., Merajver, S., Weber, B.L. Nat. Genet. (1996) [Pubmed]
  31. A human BRCA2 complex containing a structural DNA binding component influences cell cycle progression. Marmorstein, L.Y., Kinev, A.V., Chan, G.K., Bochar, D.A., Beniya, H., Epstein, J.A., Yen, T.J., Shiekhattar, R. Cell (2001) [Pubmed]
  32. Truncating mutations of RB1CC1 in human breast cancer. Chano, T., Kontani, K., Teramoto, K., Okabe, H., Ikegawa, S. Nat. Genet. (2002) [Pubmed]
  33. A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Westley, B., Rochefort, H. Cell (1980) [Pubmed]
  34. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Thompson, M.E., Jensen, R.A., Obermiller, P.S., Page, D.L., Holt, J.T. Nat. Genet. (1995) [Pubmed]
  35. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. Braun, S., Pantel, K., Müller, P., Janni, W., Hepp, F., Kentenich, C.R., Gastroph, S., Wischnik, A., Dimpfl, T., Kindermann, G., Riethmüller, G., Schlimok, G. N. Engl. J. Med. (2000) [Pubmed]
  36. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. FitzGerald, M.G., MacDonald, D.J., Krainer, M., Hoover, I., O'Neil, E., Unsal, H., Silva-Arrieto, S., Finkelstein, D.M., Beer-Romero, P., Englert, C., Sgroi, D.C., Smith, B.L., Younger, J.W., Garber, J.E., Duda, R.B., Mayzel, K.A., Isselbacher, K.J., Friend, S.H., Haber, D.A. N. Engl. J. Med. (1996) [Pubmed]
  37. Steroid hormone receptors compete for factors that mediate their enhancer function. Meyer, M.E., Gronemeyer, H., Turcotte, B., Bocquel, M.T., Tasset, D., Chambon, P. Cell (1989) [Pubmed]
  38. BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. Anderson, S.F., Schlegel, B.P., Nakajima, T., Wolpin, E.S., Parvin, J.D. Nat. Genet. (1998) [Pubmed]
  39. BRCA2 mutations in primary breast and ovarian cancers. Lancaster, J.M., Wooster, R., Mangion, J., Phelan, C.M., Cochran, C., Gumbs, C., Seal, S., Barfoot, R., Collins, N., Bignell, G., Patel, S., Hamoudi, R., Larsson, C., Wiseman, R.W., Berchuck, A., Iglehart, J.D., Marks, J.R., Ashworth, A., Stratton, M.R., Futreal, P.A. Nat. Genet. (1996) [Pubmed]
  40. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Meijers-Heijboer, H., van den Ouweland, A., Klijn, J., Wasielewski, M., de Snoo, A., Oldenburg, R., Hollestelle, A., Houben, M., Crepin, E., van Veghel-Plandsoen, M., Elstrodt, F., van Duijn, C., Bartels, C., Meijers, C., Schutte, M., McGuffog, L., Thompson, D., Easton, D., Sodha, N., Seal, S., Barfoot, R., Mangion, J., Chang-Claude, J., Eccles, D., Eeles, R., Evans, D.G., Houlston, R., Murday, V., Narod, S., Peretz, T., Peto, J., Phelan, C., Zhang, H.X., Szabo, C., Devilee, P., Goldgar, D., Futreal, P.A., Nathanson, K.L., Weber, B., Rahman, N., Stratton, M.R. Nat. Genet. (2002) [Pubmed]
  41. Absence of rearrangements in the tumour susceptibility gene TSG101 in human breast cancer. Steiner, P., Barnes, D.M., Harris, W.H., Weinberg, R.A. Nat. Genet. (1997) [Pubmed]
  42. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Boehm, J.S., Zhao, J.J., Yao, J., Kim, S.Y., Firestein, R., Dunn, I.F., Sjostrom, S.K., Garraway, L.A., Weremowicz, S., Richardson, A.L., Greulich, H., Stewart, C.J., Mulvey, L.A., Shen, R.R., Ambrogio, L., Hirozane-Kishikawa, T., Hill, D.E., Vidal, M., Meyerson, M., Grenier, J.K., Hinkle, G., Root, D.E., Roberts, T.M., Lander, E.S., Polyak, K., Hahn, W.C. Cell (2007) [Pubmed]
  43. Proteomics demonstration that normal breast epithelial cells can induce apoptosis of breast cancer cells through insulin-like growth factor-binding protein-3 and maspin. Toillon, R.A., Lagadec, C., Page, A., Chopin, V., Sautière, P.E., Ricort, J.M., Lemoine, J., Zhang, M., Hondermarck, H., Le Bourhis, X. Mol. Cell Proteomics (2007) [Pubmed]
  44. Breast cancer antiestrogen resistance-3 expression regulates breast cancer cell migration through promotion of p130Cas membrane localization and membrane ruffling. Schrecengost, R.S., Riggins, R.B., Thomas, K.S., Guerrero, M.S., Bouton, A.H. Cancer Res. (2007) [Pubmed]
  45. Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Hua, S., Kallen, C.B., Dhar, R., Baquero, M.T., Mason, C.E., Russell, B.A., Shah, P.K., Liu, J., Khramtsov, A., Tretiakova, M.S., Krausz, T.N., Olopade, O.I., Rimm, D.L., White, K.P. Mol. Syst. Biol. (2008) [Pubmed]
  46. Intratumoral estrogen disposition in breast cancer. Haynes, B.P., Straume, A.H., Geisler, J., A'Hern, R., Helle, H., Smith, I.E., Lønning, P.E., Dowsett, M. Clin. Cancer Res. (2010) [Pubmed]
  47. Brain-derived neurotrophic factor and neurotrophin-4/5 are expressed in breast cancer and can be targeted to inhibit tumor cell survival. Vanhecke, E., Adriaenssens, E., Verbeke, S., Meignan, S., Germain, E., Berteaux, N., Nurcombe, V., Le Bourhis, X., Hondermarck, H. Clin. Cancer Res. (2011) [Pubmed]
  48. Dose-response effect of adjuvant chemotherapy in breast cancer. Bonadonna, G., Valagussa, P. N. Engl. J. Med. (1981) [Pubmed]
  49. 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. Fisher, B., Carbone, P., Economou, S.G., Frelick, R., Glass, A., Lerner, H., Redmond, C., Zelen, M., Band, P., Katrych, D.L., Wolmark, N., Fisher, E.R. N. Engl. J. Med. (1975) [Pubmed]
  50. Progesterone receptors as a prognostic factor in Stage II breast cancer. Clark, G.M., McGuire, W.L., Hubay, C.A., Pearson, O.H., Marshall, J.S. N. Engl. J. Med. (1983) [Pubmed]
  51. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. Stadtmauer, E.A., O'Neill, A., Goldstein, L.J., Crilley, P.A., Mangan, K.F., Ingle, J.N., Brodsky, I., Martino, S., Lazarus, H.M., Erban, J.K., Sickles, C., Glick, J.H. N. Engl. J. Med. (2000) [Pubmed]
  52. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. Lippman, M.E., Allegra, J.C., Thompson, E.B., Simon, R., Barlock, A., Green, L., Huff, K.K., Do, H.M., Aitken, S.C., Warren, R. N. Engl. J. Med. (1978) [Pubmed]
WikiGenes - Universities